High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

Blood

Volumn 117, Issue 12, 2011, Pages 3353-3362

  Quintarelli, Concetta ^a,b,c   Dotti, Gianpietro ^a,d   Hasan, Sayyeda T ^a   De Angelis, Biagio ^a,b,c   Hoyos, Valentina ^a   Errichiello, Santa ^b,c   Mims, Martha ^d   Luciano, Luigia ^b,c   Shafer, Jessica ^a,e   Leen, Ann M ^a,e   Heslop, Helen E ^a,d,e,f   Rooney, Cliona M ^a,d,e   Pane, Fabrizio ^b,c   Brenner, Malcolm K ^a,d,e,f   Savoldo, Barbara ^a,e  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e TEXAS CHILDREN S HOSPITAL   (United States)

^f HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CHROMIUM 51; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN; MESSENGER RNA; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKEMIA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79953124445     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-300376     Document Type: Article

References (43)

1. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233-240.
2. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110(8):2838-2845. (Pubitemid 350006936)
3. Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23(35):8942-8949. (Pubitemid 46211479)
4. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105(5):1898-1904. (Pubitemid 40731770)
5. Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111(3):1357- 1365. (Pubitemid 351213422)
6. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365(9460):657-662. (Pubitemid 40260886)
7. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program. 2003:331-349.
8. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001;193(1):73-88. (Pubitemid 32060699)
9. Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G. PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res. 2007;31(3):365-369. (Pubitemid 46073179)
10. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794-2799.
11. van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol. 1998;102(5):1376-1379. (Pubitemid 28435230)
12. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2002;138(1):89-91. (Pubitemid 35292607)
13. Küppers R, Klein U, Schwering I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest. 2003;111(4):529-537. (Pubitemid 36228010)
14. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122(6):835-847. (Pubitemid 41345202)
15. Sakashita A, Kizaki M, Pakkala S, et al. 9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro. Blood. 1993;81(4):1009-1016. (Pubitemid 23054839)
16. Oehler VG, Guthrie KA, Cummings CL, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood. 2009;114(15):3299-3308.
17. Quintarelli C, Dotti G, De AB, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008;112(5):1876-1885.
18. Griffioen M, Kessler JH, Borghi M, et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res. 2006;12(10):3130-3136. (Pubitemid 43837361)
19. Pascolo S, Schirle M, Guckel B, et al. A MAGE-A1 HLA-AA*0201 epitope identified by mass spectrometry. Cancer Res. 2001;61(10):4072-4077. (Pubitemid 32720973)
20. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100(12):4059-4066. (Pubitemid 35396873)
21. Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for posttransplant lymphoproliferative disease. Am J Transplant. 2005;5(3):566-572. (Pubitemid 40313349)
22. Palandri F, Iacobucci I, Martinelli G, et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMAWorking Party on CML. J Clin Oncol. 2008;26(1):106-111.
23. Savoldo B, Sammarelli G, Dotti G, et al. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells. Leukemia. 1998;12(3):434-440. (Pubitemid 28138230)
24. Zhu B, Chen Z, Cheng X, et al. Identification of HLA-A*0201- restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res. 2003;9(5):1850-1857. (Pubitemid 36554613)
25. Luetkens T, Schafhausen P, Uhlich F, et al. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res. 2010;34(12):1647-1655.
26. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002;9(2):123-137. (Pubitemid 34457331)
27. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999;27(10):1477-1486. (Pubitemid 29458421)
28. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86(11):4337-4343.
29. Bleakley M, Otterud BE, Richardt JL, et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood. 2010;115(23):4923-4933.
30. Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010;70(3):906-915.
31. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59(11):2675-2681. (Pubitemid 29269115)
32. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007;31(11):1521-1528. (Pubitemid 350010966)
33. Rezvani K, Yong AS, Tawab A, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood. 2009;113(10):2245-2255.
34. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol. 2004;5(7):670-677. (Pubitemid 39023295)
35. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719-1724. (Pubitemid 27421983)
36. Kawashima I, Hudson SJ, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998;59(1):1-14. (Pubitemid 28141258)
37. Amir AL, van der Steen D, Hagedoorn RS, Griffioen M, Falkenburg JH, Heemskerk MH. High avidity PRAME specific T cells derived from in vivo HLA mismatched transplantation setting potentially useful for immunotherapeutic strategies [Abstract]. Blood. 2009;114(22):1568.
38. Shen XZ, Lukacher AE, Billet S, Williams IR, Bernstein KE. Expression of angiotensin-converting enzyme changes major histocompatibility complex class I peptide presentation by modifying C termini of peptide precursors. J Biol Chem. 2008;283(15):9957-9965.
39. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 1994;54(4):1071-1076.
40. Van Elsas A, NijmanHW, van der Minne CE, et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer. 1995;61(3):389-396.
41. Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008;26(17):2911-2915.
42. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111(5):639-647. (Pubitemid 36278582)
43. Hasan AN, Selvakumar A, Doubrovina E, Riviere I, Sadelain MW, O'Reilly RJ. Artificial antigen presenting cells that express prevalent HLA alleles: A step toward the broad application of antigen-specific adoptive cell therapies. Discov Med. 2009;8(43):210-218.647.